New Vaccines for Yellow Fever Using Modified Vaccinia Virus
Author Information
Author(s): Schäfer Birgit, Holzer Georg W., Joachimsthaler Alexandra, Coulibaly Sogue, Schwendinger Michael, Crowe Brian A., Kreil Thomas R., Barrett P. Noel, Falkner Falko G.
Primary Institution: Baxter Bioscience, Biomedical Research Center, Orth/Donau, Austria
Hypothesis
Can non-replicating vaccinia virus vectors provide a safer and effective alternative to existing yellow fever vaccines?
Conclusion
The non-replicating recombinant YF candidate live vaccines induced a broad immune response after single dose administration and demonstrated an excellent safety profile in mice.
Supporting Evidence
- The recombinant live vaccines induced γ-interferon-secreting CD4- and functionally active CD8-T cells.
- Full protection against lethal challenge was conferred after a single low immunization dose of 105 TCID50.
- The vaccinia virus-based vaccines did not cause mortality following intracerebral administration in mice.
Takeaway
Scientists created new vaccines for yellow fever using a virus that doesn't make you sick, and they found that these vaccines work well and are safe.
Methodology
The study involved immunizing mice with candidate vaccines based on modified vaccinia virus and assessing their immune response and protection against lethal yellow fever virus challenge.
Potential Biases
Potential bias due to funding from Baxter Bioscience, the manufacturer of the vaccines.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Balb/c mice were used for the experiments.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website